Production (Stage)
Inhibikase Therapeutics, Inc.
IKT
$1.95
-$0.01-0.51%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -90.35% | -44.62% | -2.27% | 3.40% | -7.32% |
| Total Depreciation and Amortization | -81.84% | -85.12% | -84.98% | -84.55% | 1,429.91% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 3,434.39% | 1,431.05% | -22.35% | -18.33% | 0.79% |
| Change in Net Operating Assets | -68.59% | -12.65% | 586.66% | 227.62% | 231.12% |
| Cash from Operations | -21.31% | -5.88% | 5.24% | 15.97% | 17.58% |
| Capital Expenditure | 5.63% | -- | 100.00% | 100.00% | 94.16% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -188.92% | -417.06% | -101.91% | 174.47% | 165.73% |
| Cash from Investing | -189.10% | -417.45% | -101.91% | 173.64% | 164.93% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 25,786.51% | 1,106.09% | -55.78% | -57.90% | -95.36% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 118.09% | 100.00% | -- | -- | -- |
| Cash from Financing | 53,325.28% | 1,131.15% | -57.21% | -59.34% | -97.75% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 4,534.14% | 2,294.17% | -253.62% | 103.90% | 95.09% |